Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

@article{Nieminen2010OxycodoneCA,
  title={Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir},
  author={Tuija H. Nieminen and Nora Hagelberg and Teijo I. Saari and Mikko Neuvonen and Pertti J. Neuvonen and Kari Laine and Klaus T. Olkkola},
  journal={European Journal of Clinical Pharmacology},
  year={2010},
  volume={66},
  pages={977-985}
}
PurposeThis study aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the treatment of moderate to severe pain.MethodsA randomized crossover study design with three phases at intervals of 4 weeks was conducted in 12 healthy volunteers. Ritonavir 300 mg, lopinavir/ritonavir 400/100 mg, or placebo b.i.d. for 4 days was given to the subjects. On day 3, 10 mg… 
Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
TLDR
The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxy codone can be used at usual doses in patients requiring dialysis.
Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone
TLDR
The latest oxycodone data on special populations, including neonates, children, pregnant and lactating women, and the elderly are described and a lot of important drug interaction data have been published.
Pharmacokinetic, pharmacodynamic and pharmacogenetic aspects of oxycodone treatment in cancer pain
TLDR
YP2D6 genotypes did not influence pain control, the adverse symptoms nausea and sedation or the risk for cognitive failure in patients treated with oxycodone for cancer pain, and had no pharmacodynamic consequence.
Pharmacokinetics of Oxycodone After Intravenous and Subcutaneous Administration in Japanese Patients with Cancer Pain
TLDR
Population pharmacokinetic analysis indicated that body surface area was the influencing factor on CL and there were no pharmacokinetics differences for CL between intravenous and subcutaneous infusion, and these results provide important information for the clinical use of oxycodone injection.
Interaction of oxycodone and voriconazole—a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects
TLDR
The authors conclude that the observed symptoms were due to increased plasma concentrations of oxycodone caused by CYP3A-mediated inhibition of oxy codone metabolism by voriconazole, and interaction studies of opioid analgesics with healthy subjects are useful and provide accurate pharmacokinetic data.
Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications
TLDR
When the dosage of morphine may result in unpredictable bioavailability, like in patients with severe hepatic cirrhosis, oxycodone might be beneficial because it has higher and less variability in bioavailability between patients than morphine.
Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
TLDR
The capability of PBPK model to simulate DDI of the administered compounds and the formed metabolites of both DDI victim and perpetrator is demonstrated, however, the predictions for the formed metabolite tend to be associated with higher uncertainty than the forecasts for the administered compound.
Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
TLDR
Modeling based on estimated Ki values and plasma concentrations from the literature suggest that the orally administered azoles, particularly ketoconazole and voriconazole, have the greatest potential for inhibiting CYP3A4 pathways, as does vorIconazole for the CYP2B6 pathways.
Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S‐Ketamine and Less on Intravenous S‐Ketamine
TLDR
Rifampicin profoundly reduces the plasma concentrations of ketamine and norketamine after oral administration of S‐ketamine, by inducing mainly its first‐pass metabolism.
Respiratory depression related to multiple drug–drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone
We present a case of respiratory depression likely due to oxycodone and precipitated by fluconazole. Oxycodone demethylation is catalyzed by CYP3A4 and CYP2D6 [1], with contribution ratios of 0.54
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Voriconazole drastically increases exposure to oral oxycodone
TLDR
Clinically, lower doses of oxycodone may be needed during voriconazole treatment to avoid opioid-related adverse effects especially after repeated dosing, and pharmacodynamic effects of oxy codone were modestly increased by vorIconazole.
Effect of Telithromycin on the Pharmacokinetics and Pharmacodynamics of Oral Oxycodone
The aim of this study is to determine whether the inhibition of CYP2D6 and CYP3A4 enzyme activity with telithromycin affects the pharmacokinetics and pharmacodynamics of orally administered oxycodone
Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
TLDR
Itraconazole increased the exposure to oxycodone by inhibiting its CYP3A4-mediated N-demethylation and may increase the risk of opioid-associated adverse effects.
Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone
TLDR
To maintain adequate analgesia, dose adjustment of oxycodone may be necessary, when used concomitantly with rifampin, and the pharmacologic effects of oxy codone were modestly attenuated.
Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.
TLDR
Ritonvir can inhibit the metabolism of fentanyl significantly, so caution should be exercised if fentanyl is given to patients receiving ritonavir medication.
The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
TLDR
The kinetics of oxycodone were unaffected by amitriptyline, and oxymorphone was excreted mainly as a conjugate whereas noroxycodone was recovered mostly in an unconjugated form.
Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P‐Glycoprotein Activities
TLDR
Short‐term and steady‐state ritonavir effects on intestinal and hepatic CYP3A4/5 and P‐glycoprotein and liver function and on methadone pharmacokinetics and pharmacodynamics in healthy volunteers were determined.
Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug Transport: Insights from Methadone Interactions with Ritonavir/Indinavir
TLDR
Inhibition of both hepatic and intestinal CYP3A activity is responsible for ritonavir/indinavir drug interactions, and Methadone bioavailability was unchanged, despite inhibition of gastrointestinal P-glycoprotein activity, suggesting that this transporter does not limit methadone intestinal absorption.
Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects
TLDR
It is interesting that one subject in each study exhibited the opposite effect of ritonavir on voriconazole exposure, probably due to lack of CYP2C19, and coadministration with 100 mg BID ritonvir should be avoided, unless an assessment of the benefit/risk to the patient justifies the use.
...
1
2
3
4
5
...